Efficacy and Safety of Switching to Dolutegravir With Boosted Darunavir in Virologically Suppressed Adults With HIV-1: A Randomized, Open-Label, Multicenter, Phase 3, Noninferiority Trial: The DUALIS Study

BACKGROUND: Dolutegravir (DTG) and boosted darunavir (bDRV) are potent antiretrovirals with a high resistance barrier and might be valuable switch options for people with HIV (PWH). METHODS: DUALIS, a randomized, open-label, phase 3b, noninferiority clinical trial, compared the switch to DTG + bDRV...

Descripción completa

Detalles Bibliográficos
Autores principales: Spinner, Christoph D, Kümmerle, Tim, Schneider, Jochen, Cordes, Christiane, Heiken, Hans, Stellbrink, Hans-Jürgen, Krznaric, Ivanka, Scholten, Stephan, Jensen, Björn, Wyen, Christoph, Viehweger, Marin, Lehmann, Clara, Sprinzl, Martin, Stoehr, Albrecht, Bickel, Markus, Jessen, Heiko, Obst, Wilfried, Spornraft-Ragaller, Petra, Khaykin, Pavel, Wolf, Eva, Boesecke, Christoph
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Major Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7491710/
https://www.ncbi.nlm.nih.gov/pubmed/32965277
http://dx.doi.org/10.1093/ofid/ofaa356

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7491710/
https://www.ncbi.nlm.nih.gov/pubmed/32965277
http://dx.doi.org/10.1093/ofid/ofaa356

Ejemplares similares